Last reviewed · How we verify
HS-10374-matched placebo tablets
This is a placebo tablet formulation used as a control comparator in clinical trials of HS-10374.
At a glance
| Generic name | HS-10374-matched placebo tablets |
|---|---|
| Sponsor | Hansoh BioMedical R&D Company |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
HS-10374-matched placebo tablets are inert formulations designed to match the appearance, taste, and administration schedule of the active investigational drug HS-10374 to maintain blinding in phase 3 clinical trials. They contain no active pharmaceutical ingredient and serve as the control arm to assess the true efficacy and safety of HS-10374 relative to no treatment effect.
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis (PHASE2)
- A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis (PHASE3)
- Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis (PHASE2)
- A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis (PHASE2)
- A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |